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Abstract 
Backgrounds: Keratocystic odontogenic tumors (KCOTSs) are odontogenic tumors previously referred to as odon-
togenic keratocysts. Several studies have reported that KCOT behavior is more like that of a benign neoplasm than 
a cyst. KCOTs are locally destructive and exhibit a high recurrence rate. The objective of this study is to charac-
terize the expression of p53, p63 and p73 in KCOTs together with the relationship between their expression and 
KCOT angiogenesis and recurrence.
Material and Methods: Standard indirect immunohistochemistry using monoclonal antibodies specific to human 
p53, p63, p73 and CD105 was performed in formalin-fixed paraffin-embedded tissue sections of 39 KCOT sam-
ples. Grading of p53, p63 and p73 immunohistochemical staining was divided into three groups, whereas micro-
vessel density (MVD) was presented as the mean +/- standard deviation. Associations between p53, p63 and p73 
expression and clinical-pathological parameters were analyzed by Fisher’s exact test, whereas associations among 
MVD levels, clinical and pathological parameters and p53, p63 and p73 expression were analyzed by the Mann-
Whitney U test. Correlations among p53, p63, p73 and MVD levels were analyzed using Spearman’s correlation 
coefficients. For all analyses, p< 0.05 was considered to indicate statistical significance.
Results: p53, p63 and p73 expression was noted in 23, 32 and 26 of 39 KCOT cases, respectively. The mean 
MVD was 26.7 ± 15.8 per high-power field. In addition, correlations between the expression levels of p53, p63, 
p73 and MVD in KCOT were examined. Statistically significant positive relationships were noted for all proteins 
(p<0.001).
Conclusions: Three members of the p53 protein family are expressed in KCOTs, and their expression relates to 
angiogenesis in these tumors.
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Introduction
Keratocystic odontogenic tumors (KCOTs) are odonto-
genic tumors that were previously termed odontogenic 
keratocysts. The origin of KCOTs is believed to be the 
remnant of the dental lamina (1). Several studies have 
reported that KCOT behavior is more like that of a 
benign neoplasm than a cyst (2). KCOTs are noted in 
approximately 11% of all cysts of the jaw (3). Sixty per-
cent of the lesions are noted in people between 10 and 40 
years of age. These tumors are most commonly noted in 
the mandible, especially in the body and ramus regions 
(4). KCOT patients may present with swelling, pain and 
discharge or may be asymptomatic. KCOT may have the 
potential for local destruction and atendency for multi-
plicity, especially when the lesion isassociated with ne-
void basal cell carcinoma syndrome (NBCCS) (5,6). 
KCOTs have a high recurrence rate, reportedly between 
0% and 100% (7). Recurrence has been reported to be 
higher both in tumors associated with NBCCS (82%)
(5) and in lesions arising from the mandible (8). Most 
recurrences will present within the first 5 to 7 years 
(9), although recurrences have been reported to occur 
9 or more years after the initial treatment (10). Various 
factors support the high recurrence rate of KCOTs. The 
first factor is the KCOT growth pattern, which is loca-
lly destructive (5,11). The second factor is the KCOT 
genetic background (1). Growth of KCOT is controlled 
by the tumor suppressor gene, PTCH. PTCH will bind 
to SMO, forming a transmembrane receptor complex. 
This complex will inhibit the growth signal transduction 
of KCOTs. However, if sonic hedgehog (SHH) binds to 
PTCH, its ability to inhibit growth signal transduction is 
lost. If SMO is free from forming a complex with PTCH, 
it will activate the GLI1 protein, thus increasing the cell 
proliferation rate, which is a major contributing factor 
for the pathogenesis of KCOTs (1). 
The third factor is evidence from histological studies of 
KCOTs, demonstrating that cells in the suprabasal layer 
of KCOTs have the potential to proliferate into the con-
nective tissue layer. Moreover, mitotic figures are typi-
cally observed in this layer, supporting the proliferation 
capacity of the KCOT epithelial lining (5). 
The development of tumors involves two types of ge-
nes during tumorigenesis: proto-oncogenes and tumor 
suppressor genes (12). Tumor suppressor genes play 
an essential role in inhibiting cell proliferation, which 
is normally inhibited or involves loss of function (12). 
The major tumor suppressor gene is Tp53,which is loca-
ted on chromosome 17 (13) and acts during p53 protein 
synthesis (14). Numerous immunohistochemical studies 
including odontogenic cysts and tumors have identified 
the relationship between p53 and tumorigenesis, espe-
cially in KCOTs (14,15). 
Many new genes have been discovered and classified 
in the p53 family, including Tp63. Tp63 generates p63, 
which exhibits 60% amino acid sequence similarity with 
the p53 protein (16). From a recent study, expression 
of ∆Np63 in benign odontogenic tumors is associated 
with high-risk recurrence more than in non-aggressive, 
benign odontogenic tumors with low-risk recurrence 
(17). Moreover, p63 is expressed in greater than 50% 
of malignant odontogenic tumors compared with benign 
odontogenic non-aggressive tumors (17). p73, another 
protein in the p53 family, is also mutated in human tu-
mors (18). 
When tumor growth exceeds some stage, the tumor 
forms new blood vessels to maintain its growth. The 
process begins with acceleration of protein synthesis, 
such as synthesis of vascular endothelial growth factor 
(VEGF). VEGF is released from the tumor and attach 
to the receptor on the vessel wall. Then, the vessel will 
release an intrinsic factor to stimulate more vessel for-
mation (19).
In conclusion, tumor development requires many es-
sential factors, genes and angiogenesis. According to 
several studies, a clear relationship is noted between 
p53, p63, and p73 expression and angiogenesis (15,20). 
However, none of the previous studies have reported the 
relationship between this tumor suppressor gene family 
and angiogenesis in KCOTs. Consequently, the purpose 
of this research was to study the expression of p53, p63, 
and p73 and the relationship between these proteins and 
angiogenesis in KCOTs.
Material and Methods
In total, 39 KCOT specimens from biopsy or surgical 
specimens from the Department of Oral Pathology, Fa-
culty of Dentistry, Chulalongkorn University, Srinakha-
rinwiroj University and Rangsit University were obtai-
ned. Cases were excluded if the specimens included any 
other associated pathologies.
Histopathological slides were prepared using formalin-
fixed, paraffin-embedded archival specimens. The tissue 
sections were cut 4μm thick, initially stained with hema-
toxylin and eosin (H&E) and examined under a light mi-
croscope by 2 oral pathologists to confirm the diagnosis. 
-Immunohistochemical technique
Paraffin-embedded blocks from the tumor and positive 
controls were cut 4μm thick, placed on lysine-coated 
slides and then processed using a standard immunohis-
tochemical technique.
Monoclonal mouse anti-human p53, p63 (Dako, Den-
mark) and p73 protein (ABCAM, USA) were used. 
For angiogenesis assessment, monoclonal mouse anti-
human CD105 antibody or Endoglin (Dako, Denmark) 
was used. The tissue sections slides were treated with a 
boiling solution of freshly prepared Tris-EDTA buffer 
(pH 9.0) in a microwave for 10 minutes. After cooling 
down to room temperature, the tissue sections were 
blocked from non specific reactions with normal goat 
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serum at a dilution of 1:100 for 10 minutes. The sec-
tions were incubated in a moist chamber at 4°C over-
night with primary antibody. Each primary antibody was 
used at a dilution of 1:100. Then, slides were rinsed in 
Tris-buffered saline twice before being treated with the 
Dako EnVision+System, (Product code: K4000, Dako 
North America Inc.) ata dilution of 1:100 for 60 minutes 
at room temperature.
The immunohistochemical reaction was visualized 
by developing the slides in 3,3’ diaminobenzidine te-
trahydrocholride (Vector Laboratories, USA) and coun-
terstaining with Mayer’s hematoxylin. Then, the tissue 
sections were dehydrated, cleared and mounted. The ex-
periments were performed in triplicate.
The sections were evaluated under a Nikon Eclipse 800 
microscope (Nikon Corporation, Japan). For p53,p63 
and p73 immunoreactivity, epithelial cells in the basal-
parabasal, intermediate and superficial layers that were 
positive for p53, p63 and p73 with brown staining in the 
nucleus were exclusively scored. A mean percentage of 
positive cells was determined from the percentage of po-
sitive nuclei derived from the analysis of 100 cells in 10 
random areas at 40X magnification. Positivity for p53, 
p63 and p73 was evaluated independently by two of the 
authors (KS and SC) who were blind to the clinical-pa-
thological data. A semi-quantitative assessment of p53, 
p63 and p73 expression was performed by assigning ca-
ses to one of the three following categories: (a) score 0, 
when the stained cells were from 0 to <5% of the total 
cell population; (b) score 1, when the stained cells were 
from >5 to <50% of the total cell population; or (c) score 
2, when the stained cells accounted for >50% of the total 
cell population.
Microvessel density (MVD) quantifications were perfor-
med using a Nikon Eclipse 800 microscope according to 
the method suggested by Weidner et al. (21). The defi-
nition of a microvessel used in the present study wasthe 
definition described previously (22). Three areas with 
the highest amount of vascularization (hotspots) were 
selected under a magnification of 10X. Microvessels 
were counted in each of the three fields at 40X magni-
fication, and the mean density was reported. All slides 
were simultaneously evaluated by two observers using 
a double-headed microscope, and both observers were 
required to agree on each of the individual microvessels 
before they could be included in the count. 
-Statistical analysis
For statistical analysis, the clinical-pathological parame-
ters were grouped as follows: age below or above 37 
years (the mean age of patients); male or female; maxi-
lla or mandible; unilocular or multilocular radiolucen-
cy and local recurrence. The data were analyzed using 
SPSS software for Windows, version 22.0 (SPSS Inc., 
Chicago, IL, USA). MVD levels were expressed as the 
mean ± standard deviation (SD). Associations between 
p53, p63 and p73 expression and clinical-pathological 
parameters were analyzed by Fisher’s exact test, whe-
reas associations among MVD levels, clinical-patholo-
gical parameters and p53, p63 or p73 expression were 
analyzed using the Mann-Whitney U test. Correlations 
between p53, p63, and p73 expression and MVD were 
analyzed using Spearman’s correlation coefficients. For 
all analyses, p< 0.05 was considered to indicate statisti-
cal significance.
The study was ethically approved by the Ethical Com-
mittee, Faculty of Dentistry, Chulalongkorn University, 
Thailand.
Results
In total, 22 male (56.4%) and 16 female (43.6%) patients 
with a mean age of 37.1 ± 21.8 years were included in the 
study (range 7-84 years). The majority of lesions were 
located in the mandible (76.9%) and were demonstra-
ted to have unilocular radiolucency (74.4%). Seventeen 
patients reported local recurrence (43.6%). The differen-
tial expression of p53, p63, and p73 and MVD levels in 
KCOTs are reported in table 1. 
Immunohistochemical staining
p53 expression, N (%)
   0
   1
p63 expression, N (%)
   0
   1
   2
p73 expression, N (%)
   0
   1
   2
MVD, mean ± SD
16 (41.0)
23 (59.0)
7 (17.9)
7 (17.9)
25 (64.1)
13 (33.3)
15 (38.5)
11 (28.2)
26.7 ± 15.8
Table 1. Differential p53, p63, and p73 expression and MVD levels 
in KCOTs.
p53 expression (Fig. 1) was observed in 59.0% of ca-
ses. The majority of these cases contained between 6 
and 50% positive cells (score 1; 59.0%) followed by less 
than 5% of positive cells (score 0; 41.0%). No case exhi-
bited greater than 50% of p53-positive cells. 
p63 expression (Fig. 2A) occurred more frequently 
(82.0%) than p53. Greater than 60% of cases exhibited 
greater than 50% p63-positive cells (score 2; 64.1%), 
whereas tumors exhibiting between 6 and 50% positi-
ve cells (score 1; 17.9%) were observed with equal fre-
quency as those withless than 5% positive cells (score 
0; 17.9%). p73 expression (Fig. 2B) appeared to be less 
frequent (66.7%) than that of p63 but more frequent than 
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Fig. 1. Representative photomicrographs (X200) of p53 staining in 
the basal cell layer of KCOT cystic epithelial lining.
Fig. 2. Representative photomicrographs (X200) of high p63 and p73 expression. A) p63 staining in basal and 
suprabasal cell layersof KCOT cystic epithelial lining (X200). B) p73 staining in all layers of KCOT cystic epi-
thelial lining (X200).
that of p53. The majority of cases contained between 6 
and 50% positive cells (score 1; 38.5.0%), followed by 
less than 5% positive cells (score 0; 33.3%) and greater 
than 50% positive cells (score 2; 28.2%). 
The microvessel density representing angiogenesis is 
presented in figure 3. The mean MVD value was 26.7 ± 
15.8 per high-power field (HPF). In addition, the corre-
lations in expression levels among p53, p63, and p73 as 
well as MVD levels in KCOTs were examined. Statisti-
cally significant positive relationships were noted for all 
proteins (p< 0.001, Table 2).
-Associations between p53, p63 and p73 expression and 
clinical-pathological parameters of KCOT patients
For the association analysis of p53, p63 and p73 expres-
sion and clinical-pathological parameters, cases were 
divided into 2 groups: the low expression group (cases 
with score 0) and the high expression group (cases with 
score 1 and 2). The results are presented in table 3. In-
creased p53, p63 and p73 expression was significantly 
associated with local recurrence (p = 0.001, 0.012 and 
0.017, respectively). On the contrary, no statistically 
significant relationship was noted between p53, p63 and 
p73 expression and other clinical-pathological parame-
ters, including age, gender, location and radiographic 
features.
-Associations between MVD expression level, clinical-
pathological parameters and p53, p63 and p73 expres-
sion in KCOT patients
Statistically significant differences in MVD expression 
level were demonstrated with regard to local recurrence 
and p53, p63 or p73 expression (p< 0.05). Higher MVD 
levels were detected in the cases with local recurrence (p 
= 0.012), high p53 expression (p< 0.001), high p63 ex-
pression (p = 0.006) and high p73 expression (p< 0.001). 
No statistically significant relationship was noted bet-
ween MVD level and other clinical-pathological para-
meters, including age, gender, location and radiographic 
features, (Table 4).
Discussion
In previous studies, KCOTs were considered to be tu-
mors rather than cysts due to their invasiveness and abi-
lity to form new vessels (21). These lesions appear to 
have an intrinsic growth potential and a marked tenden-
cy to recur. The epithelium of KCOTs is relatively thin 
and fragile, which enables budding of the basal layer 
into the underlying connective tissue and gives rise to 
what have been termed daughter cysts (1). 
p53 mutations are amongst the most common genetic 
alterations in human cancer. Several studies demonstra-
te that p53 expression correlates with tumor grade and 
recurrence (23). Alterations in the p63 gene have been 
proposed as one of the factors responsible for tumori-
genesis in oral cancer. Thus, p63 gene mutations may 
be considered a prevalent finding in malignancies of the 
oral mucosa (24). p73, which appears to be less studied, 
also exhibits a relationship with tumor invasiveness and 
response to treatment in oral squamous cell carcinoma. 
Many studies have demonstrated that mutations in the 
p53, p63 and p73 tumor suppressor genes are frequently 
detected in human cancers (25). Our study demonstra-
ted p53, p63 and p73 expression in the epithelial layer 
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P53 P63 P73 MVD
p53 0.88 (p < 0.001) 0.82 (p < 0.001) 0.68 (p < 0.001)
p63 0.84 (p < 0.001) 0.76 (p < 0.001)
p73 0.69 (p < 0.001)
MVD
Table 2. Correlations between p53, p63, and p73 expression and MVD levels in KCOTs, Spearman’s rho 
(p-value).
Fig. 3. Representative photomicrographs (X200) of p53 staining in 
the basal cell layer of KCOT cystic epithelial lining.
Clinical-pathological parameters p53 expression p63 expression p73 expression
High Low p-valuea High Low p-valuea High Low p-valuea
Age (years)
 ≤ 37
 >37
Gender
   Male
   Female
Location
   Maxilla
   Mandible
Radiographic features
Unilocular
Multilocular
Recurrence
   Present
   Absent
11
12
11
12
4
19
17
6
15
8
10
6
11
5
5
11
12
4
2
14
0.516
0.325
0.444
1.000
0.001
17
15
17
15
6
26
22
10
  17
15
4
3
5
2
3
4
7
0
0
7
1.000
0.438
0.319
0.158
0.012
13
13
13
13
5
21
19
7
15
11
8
5
9
4
4
9
10
3
2
11
0.734
0.318
0.447
1.000
0.017
Table 3. Relationship between p53, p63 and p73 expression and clinical-pathological parameters of KCOT patients.
a Statistically significant p-values are indicated in bold typeface.
of KCOTs in 23, 32, and 26 of 39 cases, respectively. 
This expression correlates with tumor recurrence, which 
has not been demonstrated in previous studies. Positive 
p53, p63 and p73 staining was primarily noted in the 
basal and parabasal layers, whereas the superficial layer 
was negative. These results are consistent with the study 
performed by Muzio (20) and Varsha (26), whereas the 
study from Gurgel (15) observed p53 expression mainly 
in the suprabasal layer and p63 expression in all of cys-
tic epithelial lining, including the superficial layer. Our 
study also contrasts with the study by Li, noting that p53 
expression primarily occurred in the suprabasal layer 
(27). Interestingly, our study is the first to demonstrate 
p73 expression and recurrence in KCOTs; meanwhile, 
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p73 expression is associated with recurrence of colon 
carcinoma (28).
One of the most important factors in tumor growth is 
angiogenesis. Angiogenesis is typically defined as the 
growth of new blood vessels. Angiogenesis in oral squa-
mous cell carcinoma is related to tumor recurrence (29). 
Our study shows that KCOT recurrence relates with 
angiogenesis and p53 protein family expression, which 
supports the idea of the tumor nature of KCOTs. Mo-
reover, our results correspond with those from the study 
of Gadbail et al. (30), indicating numerous microves-
sels expressing CD105 with intense immunoreactivity 
in KCOTs.
The results of this study suggest that p53, p63 and p73 
expression might reflect the replication potential of epi-
thelium that may favor tumorigenesis. This finding su-
pports the hypothesis that KCOTs exhibit more neoplas-
tic characteristics (17,20). Moreover, the relationship 
between p53, p63 and p73 expression and angiogenesis 
could suggest the proliferative ability and modulation 
of tumor angiogenesis, which may support the tumor 
nature of KCOTs. In the next World Health Organiza-
tion (WHO) classification of odontogenic cysts and 
Clinical-pathological variables MVD expression, mean ± SD p-valuea
Age (years)
≤ 37
> 37
Gender
   Male
   Female
Location
   Maxilla
   Mandible
Radiographic features
Unilocular radiolucency
Multilocular radiolucency
Recurrence
   Present
   Absent
p53 expression
   High
   Low
p63 expression
   High
   Low
p73 expression
   High
   Low
24.48 ± 15.85
29.33 ± 15.71
23.68 ± 14.53
30.00 ± 17.21
23.11 ± 16.96
27.80 ± 15.54
27.31 ± 16.26
25.00 ± 14.94
34.06 ± 13.09
21.05 ± 15.56
35.39 ± 12.01
14.25 ± 11.73
30.19 ± 15.08
10.86 ± 6.59
34.96 ± 12.41
10.23 ± 5.02
0.631
0.147
0.616
0.784
0.012
<0.001
0.006
<0.001
Table 4. Summary of study variables grouped by MVD expression in KCOTs.
a Statistically significant p-values are indicated in bold typeface.
odontogenic tumors, regardless of whether KCOTs are 
reclassified as cysts or tumors, they should be regarded 
as aggressive lesions given that our study confirms their 
neoplastic nature through p53 protein family expression 
and angiogenesis.
Conclusions
In KCOTs, p53, p63 and p73 expression and CD105-po-
sitive microvessels were observed. Moreover, p53, p63 
and p73 expression correlated with MVD in KCOTs. 
This evidence supports the theory of the highly intrinsic 
growth potential of the KCOT epithelium and tumor an-
giogenesis. Thus, it can be concluded that p53, p63 and 
p73 expression and increased angiogenesis may contri-
bute to the locally aggressive and invasive behaviors of 
KCOTs.
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